导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.73% | 2601/4773 |
| 近一周 | -1.80% | 1411/5462 |
| 近一月 | -3.38% | 2151/5421 |
| 近一季 | -6.32% | 2277/5209 |
| 近半年 | -1.71% | 1857/4920 |
| 近一年 | 1.72% | 2458/4366 |
| 近两年 | 45.77% | 1650/2954 |
| 近三年 | 28.02% | 1174/2253 |
| 成立以来 | 141.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.56% 3282/4961 |
12.16% 2218/5312 |
- - |
- - |
| 2025 | 19.03% 2258/4813 |
-1.03% 2543/3635 |
2.08% 1890/4076 |
17.88% 2410/4524 |
-0.06% 2332/4813 |
| 2024 | 16.57% 792/3463 |
2.85% 688/2808 |
-1.00% 888/3014 |
16.55% 1425/3129 |
-1.77% 1821/3463 |
| 2023 | -8.72% 1051/2656 |
4.43% 957/2280 |
-3.78% 898/2385 |
-2.73% 733/2515 |
-6.61% 1845/2655 |
| 2022 | -18.84% 764/2207 |
-13.80% 842/1919 |
7.05% 540/2016 |
-13.62% 935/2113 |
1.82% 1126/2208 |
| 2021 | -2.20% 839/1822 |
-2.73% 696/1255 |
4.59% 868/1330 |
-5.32% 794/1466 |
1.54% 887/1822 |
| 2020 | 32.91% 470/1250 |
-9.29% 668/1028 |
13.56% 610/1067 |
13.91% 305/1164 |
13.27% 375/1184 |
| 2019 | 38.08% 319/1092 |
26.68% 385/754 |
-0.09% 215/804 |
1.80% 356/850 |
7.16% 476/918 |
| 2018 | -22.65% 254/834 |
- - |
- - |
- - |
-11.84% 362/691 |
| 2017 | 23.65% 134/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.05% 239/605 |
- - |
- - |
- - |
- - |
| 2015 | 3.95% 227/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.40% 74/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.12% 108/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.28% 56/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.86% 67/102 |
- - |
- - |
- - |
- - |
| 2010 | -12.31% 34/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方沪深300ETF联接A VS. 长安沪深300非周期A(740101) |